TheraVet: Market-making Agreement with Banque Rothschild
28 Mars 2022 - 07:30AM
Business Wire
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET) (Paris:ALVET)
(Brussels:ALVET), a biotech company developing pioneering
treatments for osteoarticular disease in pets, has formed a
market-making agreement with Banque Rothschild Martin Maurel in
Paris.
The aim of the agreement is to provide liquidity in the market
for TheraVet shares and ensure that its shares can be regularly
traded, and to avoid any unjustified price discrepancies, without
interfering with the proper functioning of the market, in
accordance with Euronext market rules.
To facilitate the implementation of the market-making agreement,
Enrico Bastianelli has lent 10,000 TheraVet shares free of charge
to Banque Rothschild Martin Maurel. Swiss Life Banque Privée, in
its capacity as the IPO Listing Sponsor, has agreed to waive the
lock-up requirement in respect of those shares.
The market-making agreement has an unlimited term and will take
effect on 28 March 2022.
Next press release: 2021 Full-year annual
results April 6, 2022 before market opening
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for companion animals. The Company
develops targeted, safe and effective treatments to improve the
quality of life of pets suffering from joint and bone diseases. For
pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris and Brussels, has its head office
in Belgium (Gosselies) with a US subsidiary in Texas.
For more information, visit the TheraVet website
Or follow us on LinkedIn / Facebook / Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220327005052/en/
TheraVet Chief Operating Officer
Sabrina Ena investors@thera.vet Tel: +32 (0) 71 96 00 43
Chief Corporate Officer Julie Winand
investors@thera.vet
NewCap Investor Relations and Financial Communications
Théo Martin / Olivier Bricaud theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15
NewCap Belgique Press Relations
Laure-Eve Monfort lemonfort@newcap.fr Tél. : + 32 (0) 489 57 76
52
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024